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 Juvenile angiofibroma (JA) is an uncommon, vascular, benign, locally aggressive 
tumor. It is found almost exclusively in young males. Common presenting  symptoms 
include nasal obstruction and epistaxis. The evaluation of patients with JA relies on 
diagnostic imaging. Preoperative biopsy is not recommended. The mainstay of treatment 
is resection combined with preoperative embolization. Endoscopic surgery is the 
approach of choice in early stages while in advanced stages open or endoscopic 
approaches are feasible in expert hands. Postoperative radiotherapy (RT) or stereotactic  
radiosurgery are considered for lesions that have been subtotally resected. Patients with 
apparently incompletely  resectable JAs are best managed with moderate dose RT alone. 
There is no advantage to performing a subtotal resection followed by RT versus RT alone 
and the former is more morbid. Chemotherapy and hormone therapy are ineffective. The 

















 The cellular, vascular and locally aggressive tumor that characteristically develops 
in the posterior nasal cavity of adolescent males1, is generally referred to as juvenile 
nasopharyngeal angiofibroma Because of previous uncertainty regarding the precise 
origin of the tumor, it has been described using various names in the literature. Chelius2 
in 1847 described this lesion as a "fibrous nasal polyp which commonly occurs in persons 
around the time of puberty". It has also been known as juvenile nasopharyngeal angioma 
(Chaveau)3, vascular fibroma (Frieberg)4, juvenile nasopharyngeal hemangiofibroma5, 
juvenile fibroangioma6 and juvenile fibroma.7 However, given the origin of the tumor 
from the pterygopalatine fossa close to the vidian canal canal, the term juvenile 
angiofibroma (JA) seems preferable and is used here. 
 JA is regarded as a benign tumor.1 Sarcomatous, malignant transformation is 
extremely rare and attributable to prior radiotherapy (RT).8.9 Transformation of a tumor 
in the absence of previous RT has been recently described.9 JA may be associated with 
significant morbidity due to the particular anatomic location and locally destructive 
growth pattern. Management may be complex because of increased risk of severe 
hemorrhage. The present review therefore aims to explore the management of JA in the 
light of current knowledge and in conjunction with epidemiologic, pathobiologic and 
diagnostic aspects.  
Epidemiology 
 JA comprises about 0.05 % of all head and neck tumors with an incidence of 
approximately 1:150000.10,11 It is the most common benign tumor presenting in the nose 
and nasopharynx and is almost exclusively seen in young males between the ages of 9 
and 19 years.10 Occasional cases in older males have been  reported.12 Exceptional cases 
in females have also been described13,14,15,16 but should be subjected to rigorous 
pathologic and genetic review. The incidence seems higher in the Middle East and India 





 Hormonal and genetic factors have been considered to explain the almost 
exclusive occurrence of JA in young males.18   
 Hormonal influences are controversial. On the one hand, JA expresses various 
levels of estrogen, progesterone and androgen receptors;19 and an etiopathogenetic role 
for testosterone has been advocated.20,21,22 Riggs et al.23 observed that exogenous 
testosterone can cause tumor growth at any time, even decades following treatment. On 
the other hand correlations between proliferative index, hormonal receptors, age at 
diagnosis and tumor stage or bleeding, have not been established.19,24,25 The significance 
of puberty-induced testosteronelevels in tumor development thus remains unclear.  
 Investigations of possible genetic events,18,26 are usually based on small numbers 
of patients and clinical correlation is lacking. Chromosomal numerical gains and losses 
have been detected in both endothelial and stromal components of JA.26 These include 
deletions in chromosome 17, which affect regions of the TP53 suppressor gene and  HER-
2/NEU oncogene.27 Wnt pathways may also be involved via somatic or germ-line 
mutations of CTNNB1and APC, respectively.28 Ponti et al.29 reported nuclear staining for 
β-catenin in JAs, which is of interest because β-catenin is a coactivator of androgen 
receptors, whereas altered APC expression was only seen in JAs associated with familial 
adenomatous polyposis (FAP). Except for the association with FAP,18,28,30 JA may 
develop in patients with Gardner’s syndrome and chromosomal aberrations have been 
reported.31 
 JA overexpresses receptors for vascular endothelial growth factor (VEGFR2),29 
which may explain the growth of the tumor vascular component. Immuno-expression of 
stromal tenascin-C (TNC) in tumor stroma correlates with vascular density and higher 
tumor stage, and possibly influences angiogenesis.32 Loss of syndecan-2 has also been 
reported, which could enhance the migration of tumor cells and account for difficulties in 
surgical control of tumor margins.32 Other investigations drew attention to a correlation 
between overexpression of FGF18 and AURKB in stromal cells and down regulation of 
androgen receptors in endothelial cells.26 
 A possible role for human herpes simplex virus-8 (HSV-8), Epstein-Barr virus 
(EBV) and human papilloma virus (HPV) has also been considered.25 Although JA does 
not appear  to be associated with HSV-8 or EBV there is evidence of HPV infection at 
DNA and protein levels.33  HPV is also likely to increase cell proliferation rate in JA33, 
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and may be a possible etiologic or aggravating factor effecting early 
presentation/recurrent disease and accounting for variability in clinical behavior, 
respectively.33 
 Except for gender and age preference, the characteristic location of JA is 
intriguing. This could be explained if the tumor is regarded as a vascular malformation 
related to incomplete regression of the first branchial arch artery. Remnants of the artery 
may be preserved at the area of the sphenopalatine foramen, the typical site of JA, and 
could be sensitive to growth stimulation around puberty resulting in JA.34 The notion is 
further explored in ‘Pathology’ below and can be reconciled with molecular events, 
though some authors consider it unlikely.32 
Site of  origin and progression routes 
 JA usually originates in the posterior nasal cavity, near the basisphenoid and the 
superior margins of the sphenopalatine foramen. The tumor shows an expansive and 
destructive growth pattern; and spreads to adjacent nasal cavity, nasopharynx, paranasal 
sinuses, orbit and skull base through foramina and fissures. Normal tissues are displaced 
and affected by pressure rather than invasion. Dumbbell-shaped extension into the 
pterygopalatine space, masticator space and infratemporal fossae often occurs.35 
Cavernous sinus or intracranial extension is noted in 10-20% of the cases.36 Intradural 
involvement is exceptional. 
Pathology 
 Grossly, JAs appear as rounded or lobulated, reddish or red-purple masses, sessile 
or pedunculated.37,38 They are well circumscribed (Figures 1A and B), though non-
encapsulated, and there may be areas of ulceration or purulent exudate on the surface. 
Depending on degree of vascularity, the cut surface appears solid or spongy with smooth 
"cysts/ openings" corresponding with distended vessels. 
 Histologically, JA shows vascular and stromal components (Figure 1C).37,39 The 
vessels range from narrow-caliber and slit-like to irregularly outlined, ectatic channels in 
‘stag horn’ or ‘pericytomatous’ arrangements (Figure 1D). They are lined by a single 
endothelial layer and variously surrounded by poorly-developed, 'myoid' cells variably 
resembling smooth muscle fibres (Figures 1A-H). Elastic laminae or definite muscular 
coats are not seen, and a structural ‘leaky’ appearance (Figure 1I) accounts for the finding 
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of thrombi therein and clinical bleeding even after minor manipulation. The stroma is 
often moderately cellular and collagenous (Figure 1C). The cells are spindled, plump, 
stellate or angular often with dispersed chromatin and small nucleoli (Figures 1J and 1K); 
and varying in distribution between different tumors and areas of the same tumor. 
Multinuclear forms may be detected. The interstitial matrix ranges from fibrillary to 
hyalinised; myxoid areas may be present (Figure 1L). Overall, cytology is bland, and 
significant atypia or mitotic activity is not seen (Figure 1J). Necrosis, if present, is 
attributable to pre-operative embolization. Embolic material may be seen in vascular 
lumina (Figure 1A). Small nerves and seromucinous glands can be trapped within the 
growing tumor. The overlying epithelium is often respiratory epithelium, with areas of 
squamous metaplasia or ulceration. The latter results in reactive changes, like mixed 
inflammatory-cell infiltration and formation of vascular granulation tissue. 
 Electron microscopy shows a focal lack of pericytes, discontinuous basement 
membranes and irregular muscular coat, which reinforces the notion of ‘leaky’ vessels 
and suggests that JA is a vascular malformation rather than a neoplasm.40 Stromal cells 
are often fibroblasts, though myofibroblasts are also present. The latter are demonstrable 
on immunohistochemistry for smooth muscle actin.41,42 The vascular endothelium 
expresses CD34, CD31, von Willebrand factor, and endoglin.43,44 The stromal cells do 
not stain for CD34. It has been suggested that microvessel density in JA assessed by 
means of immunohistochemistry for endoglin, correlates with recurrence.44 Confirmation 
is desirable but clinical value, if any, remains to be seen. The expressioin of androgen 
receptors, VEGFR2 and tenascin in JA, has already been mentioned (see 
‘Etiopathogenesis’). 
 The histological diagnosis of JA does not usually pose a problem for the 
experienced head and neck pathologist, particularly when excised specimens are 
examined. Inflammatory sinonasal polyps, pyogenic granuloma,45,46 
glomangiopericytoma and solitary fibrous tumor should be considered in the differential 
diagnosis but in our opinion, the diagnostic difficulties have been over-emphasised, even 
in cases of hyalinised  inflammatory sinonasal polyps.47,48,49,50 Distinction from the rare 
sinonasal, vascular leiomyoma may be more challenging, though clinical setting, gender, 
age and site should be of help. Diagnosis on superficial incisional biopsies may pose 
difficulties, particularly in the presence of superficial ulceration, but such biopsies must 
be avoided when JA is suspected (see ‘Clinical Features and Diagnosis’ below). 
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Clinical Features and Diagnosis 
 Recurrent, unprovoked, painless, profuse, unilateral epistaxis (60%) and unilateral 
nasal obstruction (80%) with rhinorrhea, is the usual clinical presentation. Nasal 
examination is recommended for every young male with these symptoms to exclude JA. 
Less common symptoms include headaches (25%) secondary to the obstruction of the 
paranasal sinuses; and conductive hearing loss secondary to serous otitis media from 
compression of the Eustachian tube. Progressive expansion leads to sinonasal symptoms 
and facial swelling (10-40%).51 Visual and neurological deficits may appear when the 
orbit, skull base or endocranium are affected.52 Symptoms are generally present for 6 
months to a year before diagnosis and theaverage delay between symptom onset and 
surgery is around 12-14 months.54 
 Modern imaging techniques enable earlier recognition; patients present at an 
earlier stages, and compressive and neurological symptoms are less frequent. Still, up to 
40% of cases are diagnosed at an advanced-stage (see ‘Staging’ below) with up to 17% 
showing intracranial extension.53 Delay in presentation is attributable to the  association 
of  indolent symptoms of JA with more common diseases such as rhinitis, sinusitis and 
antrochoanal polyps.  
 Pre-operative diagnosis is based on clinical and imaging features; incisional 
biopsy may lead to massive bleeding and is not recommended.55 Rhinoscopy usually 
reveals a reddish lobulated mass located at the back of the nasal cavity and the cavum, 
often lobulated and firm (Figure 2). 
Imaging 
 Routine pre-operative imaging confirms the diagnosis, defines tumor extension 
and staging, and assists in treatment planning. In addition, it is used post-operatively to 
assess tumor persistence or recurrence.56 
 Computed tomography (CT), magnetic resonance imaging (MRI) and 
angiography assist in defining location, relationship to important neurovascular structures 
and assessment of blood supply to select the least traumatic approach for hemostatic 
control (Figures 3 and 4). CT is superior in outlining bony landmarks, and demonstrating 
bone erosion and invasion of the sphenoid, a significant predictor of recurrence. CT is 
more accurate for intraoperative image-based navigation. It is useful to get a CT-
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angiogram for navigation since this will provide superior visualization of the internal 
carotid artery. MRI is more useful for assessing soft tissues, invasion of bone marrow and 
intracranial extension; it is also the preferred modality for follow-up due to potential for 
differentiating postoperative reparative processes from recurrence.  
 CT often shows a soft tissue mass with bone remodelling or destruction, which 
originates near the sphenopalatine foramen and extends into adjacent nasopharynx and 
pterygopalatine fossa. The Holman-Miller sign, which is the forward bowing of the 
posterior wall of the maxilla, is found in 80% of JAs but can also occur with other benign 
or malignant tumors. The pathognomonic sign of JA is erosion of the upper medial 
pterygoid plate which is found in 98% of JAs.56 Contrast injection enables diffuse, avid 
enhancement. 
 On MRI, JA shows low and medium to high signal intensities on pre-contrast T1-
and T2-weighted sequences, respectively. Intra-lesional signal voids and intense 
enhancement following contrast injection reflect flow in enlarged vessels in keeping with 
a diagnosis of JA. Diffusion coefficient (ADC) values are high and degenerative/cystic 
components may be seen. The use of MRI and fat-suppression sequences assists in 
detecting bone marrow edema, inversely related to surgical success. MRI is also useful 
in detecting intracranial, dural and intracavernous extension and shows the relations of 
the tumor to the internal carotid arteries and pituitary. Detection of dural involvement 
may be challenging, but should be suspected if enhancement is seen on post-contrast T1-
weighted images. Also, contrast-enhanced fluid-attenuated inversion recovery (FLAIR) 
sequences are reported to be sensitive in detecting leptomeningeal spread.57 MRI may 
finally assist in distinguishing fluid collections and inflammatory mucosal thickening of 
the paranasal sinuses from intra-sinus tumor extension. 
 Kukwa et al.58 reported expression of somatostatin receptors (SSTRs) in JA and 
suggested that SST analogues with an affinity for SSTR2 may be used in pre- and 
postoperative assessment via (99m)TC-octreotide scintigraphy. 
Angiography and embolization 
 Bilateral carotid angiography is required to assess the vascular supply of JA and 
allow embolization of feeding vessels prior to surgery.59 Occlusion of feeders reduces 
intra-operative bleeding, a major cause of morbidity, and may shrink the tumor. This 
10 
 
enables better visualization of the surgical field, particularly in an endoscopic setting, 
facilitates dissection 60 and  increase chances of complete resection, a factor influencing 
recurrence.61 Most authors endorse embolization, though a few question its value on the 
basis of possible distortion of tumor boundaries, leading to incomplete resection.62,63 
 Reservations apart, pre-operative embolization is now regarded as an important 
component of management. It results in a 70% reduction of intra-operative blood loss, 
thus alleviating morbidity and need for blood transfusions.60,64,65,66 Blood loss is 
significant with JA (mean, 1,449 ml), and reinforces careful selection and preoperative 
workup of patients.53 Wasl et al.67 reported that homologous blood transfusion can be 
avoided with pre-operative cell saver and autologous blood banking. Others support the 
latter, but caution against the former because of possible autoinoculation.68 
 The vascular supply of JA largely derives from the external carotid artery and its 
internal maxillary and ascending pharyngeal.69 Occasionally, JA is supplied by both 
external carotid arteries.59.70 Bilateral embolization of the internal maxillary arteries may 
be performed in such cases, to prevent collateral blood supply. It is also noted that 
embolizing deep temporal branches of the external carotid artery that supply the 
temporalis muscle may compromise reconstruction. As tumors enlarge, additional blood 
supply is derived from branches of the internal carotid artery, predominantly the vidian 
artery. Although feeders from the internal carotid artery may be embolized51, the risk of 
serious complications such as stroke, visual loss, facial paralysis, or carotid dissection is 
increased and is not routinely performed.   The ophthalmic artery is not embolized due to 
the risk of visual loss. 
 Embolization should be performed 24-48 hours before surgery (Figure 4).71 It is 
usually effected via super-selective catheterization of supplying arterial branches. 
Embolic substances include poly vinyl alcohol (PVA), coils, micro-particles or liquid 
glue. The ethylene–vinyl alcohol co-polymer (Onyx®), shows technical advantages 
enabling deep penetration into the tumor, with more extensive tumor necrosis, 
embolization of large portions of the tumor via fewer catheterizations and safe withdrawal 
of the catheter despite possible substantial reflux.72 Successful arterial embolization with 
any of these embolic agents may be limited by vessel tortuosity, vasospasm, or prior 
sacrifice of the internal maxillary artery or external carotid artery. If the tumor feeding 
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vessels are not accessible or cannot be safely embolized, direct intra-tumoral 
embolization under, radiographic control may be undertaken.73,74,75  
 Embolization  is not without complications, the most serious being loss of vision 
secondary to occlusion of the central retinal artery.76,77 The majority of complications are 
transient and amenable to clinical management.78 Transient hair loss in the occipital 
region from radiation exposure can be seen following embolization.79 
 If preoperative tumor embolization cannot be performed, attempts should be made 
to reduce intraoperative bleeding via isolation and ligation of feeding vessels (mainly 
internal maxillary artery) as part of the surgical approach before proper tumor dissection 
begins. Hypotensive general anesthesia, the use of radiofrequency coblation and other 
hemostatic devices, and meticulous dissection as well as diathermy of the sphenopalatine 
artery would be helpful.80,81,82,83 Other surgical strategies for minimizing intraoperative 
blood loss include dividing the tumor into vascular segments, cauterization of the vidian 
artery contribution, and staging of surgery.70 
 Advanced tumors with encasement of the internal carotid artery are at increased 
risk of vascular injury during surgery.  Assessment of collateral blood flow and balloon 
occlusion testing of the artery can help identify patients who can tolerate sacrifice of the 
artery if an injury occurs. Such information is helpful in determining the extent of surgery. 
In such cases, angiographic sacrifice of the artery can be performed preemptively or only 
if an injury occurs.  Most young patients will tolerate sacrifice of one carotid artery.  
Preoperative stenting of the vessel has also been used to decrease the risk of injury when 
there is tumor encasement by paragangliomas and could be applied to JA.84 
Staging systems 
 Various systems have been proposed; most are based on tumor expansion and 
intracranial extension (Table 1).11,85 Although none is universally endorsed86, that 
suggested by Radkowski et al.87(modification of Sessions et al.88) enjoys popularity. 
Snyderman et al. introduced an interesting alternative that also emphasizes the 





 Surgical resection is regarded as the treatment of choice for all stages of 
uncomplicated primary and recurrent JA.53 Radiotherapy (RT) should be reserved for 
advanced tumors with a high risk of significant morbidity or residual/recurrent disease in 
neurocritical areas.64 Hormone therapy and chemotherapy have been explored with little 
or no success. Spontaneous regression of untreated JA has been reported,92,93,94,95,96 and 
observation of residual tumors that are difficult to resect is warranted until continued 
growth is confirmed.97 
 Surgery 
 Surgery aims to achieve tumor exposure and complete resection with the least 
possible morbidity. The extent of the initial resection influences recurrence rates. 
Multiple approaches based on tumor location and stage have been suggested.98 All have 
advantages and limitations, and selection often depends on surgical skill and experience. 
It is likely that experienced surgeons would use more conservative approaches for the 
resection of large JA. A detailed description of the different potential surgical approaches 
is beyond the scope of this review but it is noted that preferences are shifting from open 
surgery to endoscopic approaches.99,100 
 Conventional open surgery has a role in the management of JAs with significant 
intracranial and infratemporal or temporal fossa extension, or encasement of the optic 
nerve or internal carotid artery entrapment. It is usually reserved for patients with 
Radkowski IIIB tumors.99,100,101,102 Anterior open approaches include transfacial and 
transpalatal approaches. External facial or palatal incisions can be avoided in most cases 
with the use of midfacial degloving approaches. Augmentation of the midfacial degloving 
approach with a craniofacial-subcranial approach or preauricular-subtemporal-
infratemporal approach may be necessary for large tumors with extension to the anterior 
cranial fossa or middle cranial fossa, respectively. The facial translocation approach 
provides maximal access for midline tumors with lateral extension but has significant 
morbidity; equivalent results are obtained with a midfacial degloving approach combined 
with a lateral infratemporal approach.103 A lateral transorbital approach with lateral 
orbitotomy is an alternative for limited lateral skull base involvement. The midfacial 
degloving approach provides simultaneous access through the nasal cavity and maxillary 
sinus on one or both sides. A disadvantage of this approach is the relatively poor access 
to the skull base behind the tumor. Although most intracranial lesions can be safely 
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dissected from the dural surface, the complete extirpation of these tumors may be difficult 
if bleeding is severe. In these cases the standard facial translocation approach is 
applicable.104 Anterior and standard facial translocations, and the preauricular-
subtemporal-infratemporal and craniofacial-subcranial approaches are further examined. 
The versatile facial translocation is the method of choice for large tumors extending to 
the infratemporal fossa or paranasal sinuses. It allows osteotomies that enable exposure 
of the sinonasal area and infratemporal fossa; and approaching the tumor from lateral and 
antero-posterior perspectives.104 Poor access to the skull base behind of the tumor is a 
disadvantage. Although most intracranial lesions can be safely removed because the 
pushing tumor border is easily dissected from the dura, complete extirpation may be 
difficult if bleeding is severe. In these cases the standard facial translocation approach is 
applicable.104  The preauricular-subtemporal-infratemporal approach provides lateral 
access for tumors that extend into the masticator space, infratemporal fossa, middle 
cranial fossa, parasellar region, or involve the greater wing of the sphenoid bone.105 An 
orbitozygomatic osteotomy and elevation of the temporalis muscle provide exposes the 
subtemporal skull base and lateral orbit (greater wing of sphenoid).  Following excision 
of tumor, the temporalis muscle can be transposed to cover an exposed carotid artery or 
middle fossa dura. The craniofacial-subcranial approach is appropriate for intracranially 
extending JAs affecting the floor of anterior fossa, sellar region or optic chiasm.106 It is 
noted that the open procedures do not substantially affect the facial and cranial growth of 
the young patients.107 
 Transnasal endoscopic approaches are now increasingly used avoiding facial 
incisions and achieving low long-term morbidity and low recurrence rates. They are 
valuable in treating early and carefully selected, advanced JAs.70,108 When compared with 
open resection, they result in significantly less intra-operative blood loss.109,110 They do 
not preclude surgical cure64,65,111,112,113,114 and may allow access to deep structures not 
fully visualized during open surgery115,116 En bloc resection is not necessary to achieve 
surgical cure and by contrast, piecemeal resection can facilitate the approach to difficult 
anatomic areas. Initially, endoscopic approaches were used for the management of small 
(Radkowski stages I, II) tumors.117,118,119,120,121,122 The increase of endoscopic surgical 
skills together with advances in surgical instrumentation, imaging and surgical navigation 
systems enabled, however, the indication of these approaches even for Radkowski stages 
IIIA, B or UPMC stages IV and V 64,65,113,114,116,123,124,125,126.  
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 Despite endoscopic advances, challenges remain and there is no consensus on the 
management of advanced JA. Although craniofacial approaches have been the standard 
treatment, a recent review of surgical outcomes for JA with intracranial involvement, 
indicated that endoscopic resection is feasible in expert hands.53 Lateral extension of JA 
into the infratemporal fossa may be a relative contra-indication for endoscopic surgery98 
but the absence of adhesions to surrounding tissues may enable retraction of the tumor 
into the nasal cavity.51,64 Even limited intracranial penetration/dural invasion may be 
endoscopically approachable.53 The debate continues and employing endoscopy 
combined with transnasal, transfacial and transcranial approaches may be a reasonable 
compromise.127 
 Staging of surgery due to excessive intraoperative blood loss may be necessary 
for advanced tumors with significant blood supply from the internal carotid artery (UPMC 
stage IV and V), especially in young patients with a small blood volume.  In such cases, 
it is preferable to excise the extracranial component of the tumor at the first stage and 
address the intracranial component or internal carotid artery involvement in subsequent 
stages. 
 Radiotherapy 
 In general, surgical excision is the preferred treatment for all JA, regardless of 
stage, and RT should be avoided due to the unknown long-term effects in a young patient 
population. RT may be considered for advanced, incompletely resectable JA and cases 
with a high morbidity of resection. Examples include tumors with significant intracranial 
extension and encasement of the internal carotid artery. The dose fractionation schedule 
is approximately 36 Gy at 1.8 Gy per once-daily fraction. Lower doses correlate with 
higher recurrence rates.128 Intensity modulated RT (IMRT) may employed to create a 
conformal dose distribution to minimize the dose to adjacent tissues. Alternatively, proton 
RT may be used to create an even tighter dose distribution to further reduce the risk of 
late effects in these young patients. Local control rates after definitive RT range from 
85% to 91% with low riskof severe late complications.83,129,130,131  
 Stereotactic radiosurgery (SRS) is not appropriate as a sole modality to treat JAs 
because treating a large incompletely resected mass with a single high dose of irradiation 
would likely result in a higher risk of late complications.130,131,132  However, it could be 
considered for minimal, well-defined residual tumor following incomplete resection. The 
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disadvantages of SRS is a risk of marginal miss because of the necessarily tight dose 
distribution and a higher risk of late complications compared with conventionally 
fractionated RT. Stereotactic hypofractionated RT using 5 or fewer fractions has the same 
disadvantages compared with SRS. 
  In patients with advanced stage JA that are considered unresectable due to 
involvement of critical structures, an alternative to primary RT, is excision of the 
extracranial portion of the tumor, leaving a small residuum in critical areas. This may 
minimize the radiation field and potential morbidity of RT. A potential disadvantage of 
primary RT for large “inoperable” tumors is the difficulty of subsequent surgery if there 
is progressive tumor growth. However, the likelihood of progression after RT is low and 
the risk of increased complications after 36 Gy at 2 Gy per fraction is probably modest.125 
RT after unanticipated incomplete resection or recurrent JA after prior surgery is a 
reasonable option.129,133,134,135 As is the case with other benign tumors such as 
paragangliomas and meningiomas, the tumor either slowly regresses incompletely or 
remains stable after successful RT. The main risk following RT is a radiation induced 
malignancy such as a sarcoma. The risk is probably about 1 in 500 with a latency period  
of 7 to 10 years or longer.8,129,132,136 Other potential complications of RT include growth 
retardation, panhypopituitarism, temporal lobe necrosis, cataracts, and radiation 
keratopathy.131 However, the risk of late complications is very low with the dose-
fractionation schedules employed. In contrast, if a patient is at high risk for severe 
complication associated with surgery, it occurs immediately during the procedure or 
perioperatively.131 
 Chemotherapy and hormonal therapy 
 Chemotherapy or hormonotherapy are not routinely recommended.137  
 Chemotherapy has been suggested for recurrences and selected cases with 
aggressive growth.138,139  
 Hormonal therapy holds attraction because of the possible involvement of 
androgen receptors in the etiopathogenesis of JA (see above). In post-puberal patients, 
flutamide, an androgen receptor antagonist, has been used preoperatively  to achieve 
partial regression of the tumor from adjacent vital structures and allow a more 
conservative surgical approach.140 However, others failed to confirm these results.141 
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Expression of somatostatin (SST) receptors in JA suggests that their sub-typing may 
allow the use of specific SST analogues to treat residual, recurrent and inoperable 
tumors.58 
 Expression of other receptors55,142 indicates similarly variable potential. 
Tamoxifen, an estrogen receptor antagonist, inhibits proliferation of cultured JA stromal 
cells142; however, the side effects of Tamoxifen preclude from its clinical application in 
JA. Bevacizumab, a monoclonal antibody that inhibits VEGF-A, may also be of value, 
but clinical data are lacking.143 An untested, though intriguing option would be 
glucocorticoids as they seem able to downregulate VEGF, and reduce microvascular 
density and tumor volume; and their receptors are upregulated in JA.144 
Results and follow-up 
 Most, if not all, recurrences are due to incomplete resection of the primary 
tumor.145 The rate of residual disease varies from 13% to 50%.64 Although it may be 
difficult to distinguish between residual tumor and new tumor growth144 the likelihood of 
a second primary JA is remote. Residual disease may not grow or even undergo 
involution60,146 On post-operative CT and/or MRI residual/recurrent disease appears as 
areas of contrast enhancement, but healing processes may show similar appearances and 
distinction is a major radiological challenge.11,126,147  
 Chagnaud et al.147 formulated guidelines for follow-up. If the patient is 
asymptomatic, rhinoscopy is negative and imaging shows no residual mass 3 to 4 months 
after surgery, clinical review alone is recommended. If the clinical signs/symptoms 
suggest recurrent/residual tumor, a mass is visualized on rhinoscopy, and CT or MRI 
confirm tumor and indicate its extent, a second operation is performed. Finally, if the 
patient is asymptomatic, rhinoscopy is negative and enhancement outside the 
nasopharyngeal cavity is seen on the first radiological examination 3 or 4 months post-
operatively, further imaging is undertaken 3 to 6 months later. Then, if the enhancement 
has decreased in size and/or intensity, a third imaging study follows after 6 months; in 
case of resolution clinical review is adequate; if the enhancement remains stable, 
periodical imaging twice a year is recommended; if the enhancement has increased in 
size, second surgery or RT are indicated. Langdon et al.126 do not support further surgery 
for intracranial remnants, unless there is a measurable tumor growth or new symptoms. 
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 Recurrence is usually observed within 6 to 36 months after primary therapy 
53,110,126,148 which supports a minimum follow-up of 3 years.11 Most investigators use a 
combination of rhinoscopy and MRI for at least 5 years post-operatively, but periods of 
follow-up vary between institutions.64,149 Nevertheless early detection relates to better 
outcomes and some authors advocate imaging within the first month post-operatively 
(even immediately after packing is removed) to detect residual disease.150 This may 
improve its distinction from later healing processes.111 Early detected residual disease 
usually requires minimally invasive surgery and the need for repeating embolization or 
RT can be avoided. 
 Recurrences are observed in approximately 18–45% of the patients and depending 
on size, extent of tumor and surgical approach; most patients (86%) would be expected 
to be free of disease during long-term follow-up.10,17,53,118 The likelihood of recurrence is 
particularly high in patients with intracranial extension.145 Endoscopic recurrence rates 
appear lower than those of open surgery, although this may reflect the bias of early-stage 
tumors being more likely to be treated endoscopically. However there is no difference in 
recurrence rate when controlling for tumor extent.109,114 Recurrence rates for patients with 
stage I and II lesions is between 0 and 7% according to the majority of 
publications.62,65,113,114,124 Encouraged by these results, technological progress and 
increasing endoscopic skills, some authors approached advanced JA endoscopically with 
similar outcomes.64,126 
 Recurrence rates appear related to involvement of specific sites. The more sites 
involved, the higher the probability of tumor persistence.126 Involvement of the skull base, 
extension into the pterygoid fossa and basisphenoid, erosion of the clivus, intracranial 
extension medial to the cavernous sinus, invasion of the sphenoid diploe through a 
widened pterygoid canal, feeders from the internal carotid artery, young age and 
incomplete surgery are factors associated with increased risk of recurrence.40,108,110,14,151 
Howard et al.152 emphasized the significance of residual tumor in the basisphenoid and 
base of pterygoids and that meticulous removal led to cure in the majority of cases. Lloyd 
et al.56 reported that 60% of JA expand  posteriorly along the pterygoid canal with 
invasion of the cancellous bone of the sphenoid, and  noted  that 93% of recurrences 
occurred in patients with invasion of sphenoid diploe. Meticulous subperiosteal dissection 
and drilling of these areas assist in complete removal and avoiding recurrences.64,111,148,149 
Thakar et al153, reported that involvement of the vidian canal is almost universal in JA 
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and may not be detected on CT; this site may still harbor microscopic residual tumor after 
an apparently complete resection and should receive particular surgical attention to 
reduce for the chances of  recurrence. 
 Second surgery, whether open or endoscopic, appears the best option if chances 
for extirpating residual/recurrence tumor are reasonably high.60 Attempts at removing 
remnants from critical areas (cavernous sinus, internal carotid artery) do not seem 
justified because of significant morbidity.65,148,151 While residual or recurrent tumor may 
also be treated with RT or SRS with acceptable morbidity, a ‘wait and see’ policy may 
be adopted.53,64 Prospective investigations are needed to determine the optimal strategy  
Conclusion 
 JA is a rare and complex disease that may cause significant morbidity in young 
patients. Improved surgical and RT techniques, and advances in imaging and pre-
operative embolization have influenced management. Treatment planning depends on 
patient age, low likelihood of spontaneous involution, expected surgical morbidity, RT 
side effects and risk of recurrence. The benign yet aggressive nature of the tumor poses a 
dilemma as price of cure must not be worse than the disease itself.  Surgery is the main 
therapeutic option. Patients should be treated at centers with expertise in skull-base 
surgery to achieve best results in regards to complete resection and low morbidity. 
Endoscopic excision is preferable for early stage tumors due to decreased morbidity. The 
selection of open or endoscopic approaches for more advanced tumors is very dependent 
on the experience of the surgical team.  In these cases the best results may be achieved 
with a combination of open and endoscopic approaches. RT or SRS after incomplete 
resection is valuable for long-term control of extensive JA involving vital structures. 
Although definitive RT is a treatment option for extensive, incompletely resected JA, 
resectability is subjective based on the abilities of the surgical team. Hormone therapy 
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FIGURE 1. Histology of a typical JA. The photomicrographs are from sections of 
routinely processed tissue, which were stained with hematoxylin and eosin. Zooming on 
the electronic format of the photomicrographs would allow appreciation of detail, less 
perceptible on prints. (A) Non-encapsulated front of tumor (asterisk). Pre-existing glands 
and an embolized vessel are seen at the lower left and right of the picture, respectively. 
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(B) Evidence of osteo-destruction. The arrow indicates fragment of pre-existing bone 
incorporated within the growing tumor. (C) Core of tumor. Dilated lumina of ‘empty’ 
thin-walled vessels and collagenous stroma (asterisk) are seen. (D) ‘Stag horn’ vessel. (E) 
Poorly-developed ‘myoid’ coat of a vessel. Although variably demarcated, its increased 
eosinophilia allows distinction from adjacent stroma. Ocassional cells resemble 
attenuated smooth muscle fibres (arrow). (F) The increased cellularity of a tangentially 
sectioned coat (asterisk) further distinguishes it from adjacent stroma. (G) Moderately-
developed ‘myoid’ coats. In comparison with Fig. 1E, cells resembling attenuated smooth 
muscle fibres show more abundant cytoplasm. (H) Moderately-developed ‘myoid’ coat 
demarcated from adjacent stroma. Compare with Fig. 1E. (I) Vessel with incomplete 
myoid’ coat shows possible ‘gaps’ in the continuity of the endothelial lining and leakage 
of plasma (arrows). (J) Nuclear features of spindled stromal cells. Note absence of 
mitoses. A possible multinuclear form is arrowed. (K) Stellate and angular stromal cells 
(arrows). (L)  Myxoid matrix (asterisk) around vessels. 
FIGURE 2. Endoscopic nasal view of the right nasal fossa during endoscopic surgery in 
a patient with JA. The tumor appears as lobulated, pedunculated mass with smooth and 
focally hemorrhagic surface, located in the posterior nasal cavity. MT: middle turbinate; 
IT: inferior turbinate; S: septum; T: tumor 
FIGURE 3. (A) Coronal view of right external carotid angiogram prior to embolization.  
Vascularization of JA effected by distal branches of the internal maxillary artery. (B) 
Coronal view of right external carotid angiogram, after particulate and coil embolization 
of feeders. Devascularization of the tumor is almost complete. 
FIGURE 4. Coronal CT (A), axial CT (B), T1-weighted postcontrast (C) and  T2-
weighted (D) MRI images show a large mass centered in the posterior nasal cavity with 
widening of and extension into the pterygopalatine fossa. There is also extension to the 
pterygoid plates/process posteriorly. Post-resection coronal (E) and axial images (F) 
show complete resection of the tumor following an endoscopic approach. 
